Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor

In Vitro Efficient Expansion of Tumor Cells Deriving from Different Types of Human Tumor Samples

“…Cell lines generated by this method may prove useful, as in vitro models for anticancer drug testing/development, and for facilitating the clinical development of CTL-based immunotherapeutic strategies based on the use of vital tumor cells as source of tumor antigens [8,[14][15][16][17]. As previously demonstrated by our group, treatment with specific autologous antitumor CTLs in vitro generated induced immunological responses and long-lasting clinical benefit in a patient with RCC [18].…”

Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy

“…20,34 Adoptive CTL therapy has been used with clinical benefit in a range of tumor types, including hematological and nonhematological tumors. [37][38][39] Given some of the current uncertainties of APC/tumor cells as therapeutic cancer vaccines in humans, and the demonstrated ability of APC/tumor hybrid cells to induce tumor antigen-specific CTL in vitro, [16][17][18][19][20]34,35 themselves are short lived and have limited replicative capacity, limiting the numbers of fusion cells generated for use in vaccination. In addition, the nature of the processes of culture, isolation and cell fusion of DCs and ex vivo tumor cells limits standardization and characterization of the fusion cells.…”

Enhancement of antigen presenting ability in the leukemic plasmacytoid dendritic cell line (PMDC05) by lentiviral vector-mediated transduction of CD80 gene

“…Using such functions of DCs, DCbased cellular immunotherapy have been developed for tumor and recently approved as effective therapy for prostate cancer by FDA in the USA [2]. In addition to the therapy of directly infusing DCs by themselves into patients, adoptive cellular immunotherapy, that is, infusion of antigen-specific CTLs generated by priming lymphocytes with antigen-presenting CDs in vitro, has been demonstrated to be promising therapy for tumor [3]. Although encouraging data has been reported, it is technically difficult and labor-intensive to expand antigen-specific CTLs in vitro.…”